Inovio Pharma (INO) Posts Q4 Loss of 25c/Share

Inovio Pharma (NASDAQ: INO) reported Q4 EPS of ($0.25), which may not compare with the analyst estimate of ($0.20). Revenue for the quarter came in at $5.94 million versus the consensus estimate of $6.96 million.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• BitFuFu Inc. (FUFU) Misses Q2 EPS by 13c
• InspireMD (NSPR) Tops Q2 EPS by 1c